Exclusive Distribution Agreement Adds eSuction Distal Cap to Olympus EndoTherapy Portfolio

CENTER VALLEY, Pa., Oct. 17, 2019 /PRNewswire/ — Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today the U.S. launch of eSuction for removal of foreign bodies. eSuction from EndoTherapeutics combines snare technology with suction to aid in the retrieval of food bolus impactions, foreign bodies and excised tissue such as polyps. Through an exclusive distribution agreement with Olympus, eSuction is now available in the U.S.

eSuction, which is FDA registered as a Class I medical device, is designed to fit securely onto the endoscope. eSuction is the only distal cap device on label for removal of food bolus impactions and provides an efficient solution for the removal of impactions, which physicians have found commonly accompany some type of pathology.[i] It brings economic value in that it may reduce the need for an overtube in the removal of sharp foreign bodies, and it may aid in reducing procedural time by providing a combination device that limits the need for device exchange. With the addition of eSuction, Olympus continues to offer one of the most diversified portfolios for foreign body retrieval.

“Our EndoTherapy line is one of the most exciting of the Olympus businesses today,” said Kurt Heine, Group Vice President at Olympus America Inc. “We are pleased to be working with EndoTherapeutics to distribute the eSuction device, an important addition to the Foreign Body Removal line in terms of cost-savings and clinical benefits. This is an important device for our customers and their patients.”

eSuction is being made available to customers immediately and will be on display in Olympus Booth #502 at NASPGHAN, October 17-19, at the Sheraton Grand in Chicago. For more information on the devices, please contact Olympus customer service at 1-800-848-9024 or visit https://www.medical.olympusamerica.com/products/esuction

About Olympus Medical Systems Group
Olympus is a global technology leader, crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products. Throughout our 100-year history, Olympus has focused on being true to society and making people’s lives healthier, safer and more fulfilling.

Our Medical Business works with health care professionals to combine our innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing with their skills to deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance quality of life for patients. For more information, visit medical.olympusamerica.com.

[i] Ginsberg GG. Food bolus impaction. Gastroenterol Hepatol (N Y). 2007;3(2):85–86.

View original content to download multimedia:http://www.prnewswire.com/news-releases/exclusive-distribution-agreement-adds-esuction-distal-cap-to-olympus-endotherapy-portfolio-300940363.html

SOURCE Olympus

Staff

Recent Posts

AI/ML Innovations Closes Acquisition of Quantum Sciences Ltd.

Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…

1 hour ago

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

15 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

16 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

16 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

17 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

19 hours ago